Searchable abstracts of presentations at key conferences in endocrinology

ea0084op-10-47 | Oral Session 10: Young Investigators / Clinical and Translational | ETA2022

Putative protective role of anti-nuclear antibodies in graves’ orbitopathy

Lanzolla Giulia , Comi Simone , Puccinelli Lisa , Menconi Francesca , Marcocci Claudio , Marino' Michele

Objectives: A sporadic association between thyroid and non-organ-specific autoimmunity has been reported, which could be relevant for Graves’ orbitopathy (GO), an autoimmune disease affecting orbital connective tissue. We investigated whether there is an association between GO and anti-nuclear antibodies (ANAs).Methods: We performed a cross-sectional investigation in 265 consecutive patients with Graves’ disease (GD) who came to our observation...

ea0084ps2-07-58 | Graves’ Disease 1 | ETA2022

High IGG4 serum levels in graves’ disease compared with nonautoimmune hyperthyroidism

Comi Simone , Lanzolla Giulia , Giudetti Matilde , Menconi Francesca , Marcocci Claudio , Marino Michele

Objectives: A role of IgG4 in Graves’ disease (GD) has been proposed, although the available data are conflicting. In addition, an association between Graves’ orbitopathy (GO) and IgG4-related disease has been postulated, but no firm demonstration has been obtained. Thus, the aim of the present study was to investigate the role of IgG4 in GD.Methods: We performed a cross-sectional investigation in 351 consecutive patients (F=284, M=67; age 48.2...

ea0084op-05-24 | Oral Session 5: Autoimmunity | ETA2022

Sirolimus for graves’ orbitopathy: A novel drug for the management of patients with moderate-to-severe graves’ orbitopathy?

Lanzolla Giulia , Novella Maglionico Maria , Comi Simone , Menconi Francesca , Posarelli Chiara , Figus Michele , Marcocci Claudio , Marino' Michele

Background: Sirolimus is an immunosuppressive drug with anti-fibrotic and anti-proliferative activities. In vitro, sirolimus inhibits differentiation of orbital fibroblasts from patients with Graves’ orbitopathy (GO), suggesting a possible use in clinical practice.Methods: We performed a retrospective investigation aimed at evaluating the effects of sirolimus as a second-line treatment for moderate-to-severe, active GO, compared with methyl...

ea0084ps1-02-14 | Hypothyroidism | ETA2022

A case of late-onset dyshormonogenic goiter with hypothyroidism due to a homozygous mutation of SLC26A7 gene

Sciarroni Elisabetta , Comi Simone , Montanelli Lucia , Latrofa Francesco , Brancatella Alessandro , Di Cosmo Caterina , De Marco Giuseppina , Ferrarini Eleonora , Pignata Luisa , Tonacchera Massimo , Agretti Patrizia

Introduction: Congenital hypothiroidism (CH) is the most common neonatal endocrine disorder, affecting up to one in 1500 to 2000 newborns, if mild forms of hypothyroidism with eutopic and normal-sized thyroid gland are included. It is caused by either dysgenesis or dyshormonogenesis. Recently a novel iodide transporter, SLC26A7 (a member of the SLC26 transporter family), whose dysfunction affects thyroid hormonogenesis in humans, has been identified. The main purpose of this s...